Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The new indication could give Novo Nordisk a boost against rivals in the GLP-1 agonist class, including Eli Lilly, whose dual GIP/GLP-1 agonist Mounjaro (tirzepatide) competes in the diabetes category and is in a phase 3 trial (TREASURE-CKD) looking at a CKD indication in people with obesity, with and without diabetes
Cellular RPM scales bridge this gap by providing daily or weekly updates to both patients and healthcare providers
Clean the site with an alcohol swab and let it air dry completely
such as the upper arm or abdomen
Your healthcare team can also evaluate whether the benefits of continuing GLP-1 therapy outweigh the discomfort, or whether alternative diabetes or weight management strategies should be considered
